Anti-PD-1 Monoclonal Antibodies Market Estimations (2025 - 2035)

Anti-PD-1 Monoclonal Antibodies Market Estimations (2025 - 2035)

The anti-PD-1 monoclonal antibodies market covers monoclonal antibodies that block the PD-1 immune checkpoint receptor, including pembrolizumab, nivolumab, cemiplimab, dostarlimab, retifanlimab and China-developed sintilimab, tislelizumab, camrelizumab and toripalimab, in intravenous and subcutaneous forms, for lung, melanoma, kidney, head and neck, gastrointestinal and other cancers, in metastatic and early-stage settings.

📄Report ID:2508 | 📊Format: Databook | 📅Published: 18 November 2026 | ⚡Delivery: Immediate